The National Post has an article on shortages in the supply of about 10-15 generic drugs.
The generic drug companies point to manufacturing and supply problems - and remember that this is a global industry, so we're often talking about off-shore supply problems - but the journalists can't help wondering if this reflects the recent changes in generic drug pricing regimes.
Better buys time, not a barrier: what counter-positioning means for your
patent strategy
-
A better product buys a challenger time. It does not buy a barrier. The
mistake most founders make is treating the time as the win, and spending
the whole ...
3 days ago
No comments:
Post a Comment